ArticleDermatology reports2026
Stevens-Johnson syndrome and toxic epidermal necrolysis in Saudi Arabia: a retrospective cross-sectional multicenter study.
Article in Dermatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are a spectrum of life-threatening mucocutaneous conditions. Despite having a lower incidence rate than other dermatological conditions, SJS/TEN has a high mortality rate. SJS/TEN is usually caused by newly administered medications, particularly antibacterials and anticonvulsants. Little research data on SJS/TEN in Saudi Arabia has been published. We aimed to bridge this gap by reviewing and investigating the etiologies, risk factors, interventions, and outcomes of patients diagnosed with SJS/TEN. This is a retrospective cross-sectional study conducted in National Guard hospitals in Riyadh and Jeddah from January 2015 to July 2023. We reviewed all dermatology medical records diagnosed as SJS/TEN through clinical assessment and histopathology, confirmed by a dermatology consultant. Additionally, we excluded all non-Saudi patients and those referred to our center with outside reports without histopathology from the National Guard hospitals. This study included 25 patients diagnosed with the SJS/TEN spectrum between January 2015 and July 2023. Nearly two-thirds of the patients were male (n=15, 60%), and the average age was 45.96 years. Almost half of the culprit agents were antibiotics. Six of the 25 patients died (24%). Four were males, all over 50 years old, and one female was 6 years old. All these patients had TEN, except for one with SJS. Septic shock was the cause of death in 4 patients. Given the evident high risk for patients contracting this condition, prospective research and analysis to understand the correlation between SJS/TEN, mortality, and treatment are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.